Ischemic heart disease (IHD), refers to a group of diseases which includes stable angina, unstable angina, myocardial infarction, and sudden cardiac death. It is within the group of cardiovascular diseases of which it is the most common type. A common symptom is chest pain or discomfort which may travel into the shoulder, arm, back, neck, or jaw.

Scope of the Report:
This report focuses on the Ischemic Heart Disease (IHD)Drugs in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
Ways to reduce CAD risk include eating a healthy diet, regularly exercising, maintaining a healthy weight, and not smoking. Medications for diabetes, high cholesterol, or high blood pressure are sometimes used. Additional medications such as antiplatelets, beta blockers, or nitroglycerin may be recommended.
The worldwide market for Ischemic Heart Disease (IHD)Drugs is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new study.

Market Segment by Manufacturers, this report covers
AstraZeneca
Bayer
Eli Lilly
Novartis
Pfizer
Sanofi

Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers
Anti-dyslipidemic Drugs
Calcium Channel Blockers
Beta-blockers
ACE Inhibitors
ARBs
Vasodilators
Antithrombotic Agents

Market Segment by Applications, can be divided into
Stable Angina
Unstable Angina
Prinzmetal's Angina
STEMI
NSTEMI

There are 15 Chapters to deeply display the global Ischemic Heart Disease (IHD)Drugs market.
Chapter 1, to describe Ischemic Heart Disease (IHD)Drugs Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2, to analyze the top manufacturers of Ischemic Heart Disease (IHD)Drugs, with sales, revenue, and price of Ischemic Heart Disease (IHD)Drugs, in 2016 and 2017;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;
Chapter 4, to show the global market by regions, with sales, revenue and market share of Ischemic Heart Disease (IHD)Drugs, for each region, from 2013 to 2018;
Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;
Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;
Chapter 12, Ischemic Heart Disease (IHD)Drugs market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;
Chapter 13, 14 and 15, to describe Ischemic Heart Disease (IHD)Drugs sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source